Intranasal Peptides: Which Peptides Work via Nasal Administration?

Intranasal administration occupies a unique pharmacological niche. For most systemically acting drugs, the nasal route is simply an alternative delivery mechanism that produces similar blood levels to other routes. For certain peptides, however, intranasal administration offers a specific advantage: direct access to the central nervous system via the olfactory and trigeminal nerve pathways, partially bypassing the blood-brain barrier.

The Nasal-Brain Pathway

The olfactory epithelium at the top of the nasal cavity is in direct anatomical contact with the olfactory bulb of the brain, separated only by a thin layer of epithelium and no blood-brain barrier. Molecules absorbed here can enter the CNS directly via olfactory receptor neurons and their axons that project to the olfactory bulb.

The trigeminal nerve, which innervates a large portion of the nasal mucosa, provides a second pathway for perivascular delivery of drugs to the brainstem and spinal cord. Together these pathways allow small to moderately sized peptides to reach brain tissue at concentrations far exceeding what would be achieved via bloodstream delivery given the normally restrictive blood-brain barrier.

This nasal-to-brain transport is not universal. It depends on molecular weight, lipophilicity, and specific transport mechanisms. But for the cognitive peptides developed specifically for this route, it is the primary mechanism of action.

Semax and Selank: Designed for Intranasal Use

Semax and Selank were specifically designed by Russian researchers for intranasal delivery to the CNS. Their molecular weight and physicochemical properties allow efficient olfactory mucosal absorption and subsequent transport to the brain. The clinical formulations of both compounds in Russia are nasal spray preparations, not injectables.

Semax at 200 to 600 mcg intranasally produces measurable CNS effects within 30 to 60 minutes, including BDNF upregulation, dopaminergic activation, and cognitive enhancement. Selank at 250 to 500 mcg intranasally achieves anxiolytic and cognitive effects through similar nasal-to-brain delivery. Standard research powder can be reconstituted and loaded into a small nasal spray bottle or administered as drops.

Oxytocin: Social and Anxiolytic Effects

Intranasal oxytocin has been extensively studied in clinical trials and is the most clinically developed intranasal peptide. Oxytocin does not cross the blood-brain barrier efficiently via systemic administration, but intranasal delivery achieves CNS concentrations that produce measurable effects on social cognition, anxiety, trust, and empathy.

Dozens of clinical trials have evaluated intranasal oxytocin for conditions including autism spectrum disorder, social anxiety, and PTSD. Results are mixed but the mechanistic rationale is solid. Standard doses in clinical research are 24 to 40 IU administered intranasally. Commercially produced nasal oxytocin (Syntocinon) is available by prescription in some countries.

Intranasal BPC-157

BPC-157 can be administered intranasally to achieve both systemic effects via mucosal absorption and potentially direct CNS delivery through the olfactory pathway. Anecdotal reports suggest intranasal BPC-157 at 100 to 250 mcg may have neuroprotective and cognitive effects in addition to its systemic healing properties. This route is less characterized than subcutaneous injection but offers a needle-free option for users targeting CNS or systemic effects.

Administration Protocol

Intranasal peptide administration requires a suitable delivery device. Options include commercially available nasal spray bottles (adapted for reconstituted peptide solutions), Mucosal Atomization Devices (MAD) which produce a fine mist from a syringe, and simple dropper bottles or insulin syringes administering drops directly.

For effective delivery, tilt the head slightly forward (not backward, which causes the solution to run into the throat), insert the spray nozzle into one nostril, direct the spray toward the lateral wall rather than straight up, and sniff gently. Alternating nostrils and tilting side to side after administration maximizes contact time with the olfactory epithelium. Avoid blowing the nose for 5 to 10 minutes after administration.

Concentration for intranasal administration should be adjusted to deliver the target dose in a practical volume, typically 0.1 to 0.2 mL per nostril per administration. Concentrations are therefore higher than would be used subcutaneously.

FAQ

Does intranasal delivery work as well as injection for cognitive peptides? For Semax and Selank specifically, intranasal delivery is the primary intended route and may actually be superior to injection for CNS effects because of the direct olfactory pathway to the brain. For most other peptides, injection achieves higher systemic bioavailability.

Can any peptide be used intranasally? Theoretically yes, but efficacy via this route varies enormously. Peptides specifically studied and optimized for intranasal delivery (Semax, Selank, oxytocin) have the most evidence. Using other peptides intranasally may have some effect but bioavailability is uncertain.

Is intranasal administration safe? Intranasal peptide administration is generally well tolerated. Local irritation, mild burning, and nasal congestion are the most common side effects. Using isotonic concentrations and clean spray devices minimizes irritation. Do not use intranasal peptides if you have nasal polyps, severe allergic rhinitis, or nasal septal defects that would impair drug absorption.

Related Articles

• Semax: Cognitive Enhancement Peptide from Russian Nootropics Research
• Afamelanotide: FDA-Approved Melanocyte Peptide
• AOD-9604: HGH Fragment for Fat Loss
• Argireline: The Topical Peptide Alternative to Botox?
• Bacteriostatic Water for Peptides: Why It Matters and How to Use It

Track your supplements in Optimize.